Pfizer Receives CHMP Negative Opinion Regarding Marketing Authorization In Europe For Rheumatoid Arthritis Treatment XELJANZ® (tofacitinib citrate) | Pfizer Pharmaceutical News and Media | Pfizer: the world's largest research-based pharmaceutical company
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.